Search
Kymera Therapeutics Inc
KYMRAdd to Watchlist
103.400USD
-3.610-3.37%
Close 07-31 16:00（ET）Quotes delayed by 15 min
8.50BMarket Cap
LossP/E TTM
More Details of Kymera Therapeutics Inc Company
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The Company's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. It is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. It is developing KT-579, which is an investigational, first-in-class, oral degrader of IRF5, a genetically validated transcription factor and a master regulator of immunity.
Kymera Therapeutics Inc Info
Ticker SymbolKYMR
Company nameKymera Therapeutics Inc
IPO dateAug 21, 2020
CEOMainolfi (Nello)
Number of employees188
Security typeOrdinary Share
Fiscal year-endAug 21
Address500 North Beacon Street, 4Th Floor
CityWATERTOWN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02472
Phone18572855314
Websitehttps://www.kymeratx.com/
Ticker SymbolKYMR
IPO dateAug 21, 2020
CEOMainolfi (Nello)
Company Executives of Kymera Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Nello Mainolfi, Ph.D.
Dr. Nello Mainolfi, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
666.20K
--
Dr. Jared August Gollob, M.D.
Dr. Jared August Gollob, M.D.
Chief Medical Officer
Chief Medical Officer
71.36K
+19.43%
Dr. Jeremy G. Chadwick, Ph.D.
Dr. Jeremy G. Chadwick, Ph.D.
Chief Operating Officer
Chief Operating Officer
9.81K
--
Dr. Pamela Esposito, Ph.D.
Dr. Pamela Esposito, Ph.D.
Independent Director
Independent Director
1.00K
--
Dr. Gorjan Hrustanovic, Ph.D.
Dr. Gorjan Hrustanovic, Ph.D.
Independent Director
Independent Director
--
--
Mr. Jeffrey W. (Jeff) Albers, J.D.
Mr. Jeffrey W. (Jeff) Albers, J.D.
Independent Director
Independent Director
--
--
Dr. Bruce L. Booth
Dr. Bruce L. Booth
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
--
--
Ms. Elena H. Ridloff
Ms. Elena H. Ridloff
Independent Director
Independent Director
--
--
Mr. Bruce N. Jacobs
Mr. Bruce N. Jacobs
Chief Financial Officer
Chief Financial Officer
--
--
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Nello Mainolfi, Ph.D.
Dr. Nello Mainolfi, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
666.20K
--
Dr. Jared August Gollob, M.D.
Dr. Jared August Gollob, M.D.
Chief Medical Officer
Chief Medical Officer
71.36K
+19.43%
Dr. Jeremy G. Chadwick, Ph.D.
Dr. Jeremy G. Chadwick, Ph.D.
Chief Operating Officer
Chief Operating Officer
9.81K
--
Dr. Pamela Esposito, Ph.D.
Dr. Pamela Esposito, Ph.D.
Independent Director
Independent Director
1.00K
--
Dr. Gorjan Hrustanovic, Ph.D.
Dr. Gorjan Hrustanovic, Ph.D.
Independent Director
Independent Director
--
--
Mr. Jeffrey W. (Jeff) Albers, J.D.
Mr. Jeffrey W. (Jeff) Albers, J.D.
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Kymera Therapeutics Inc?
The top five shareholders of Kymera Therapeutics Inc are: Dr. Nello Mainolfi, Ph.D.
How many institutions hold shares of Kymera Therapeutics Inc (KYMR)?
As of 2026Q1, 505 institutions hold shares of Kymera Therapeutics Inc, with a combined market value of approximately 96.67M, accounting for 117.53% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 10345704.00.